Navigation Links
A search for protection against chemotherapy cardiotoxicity

Researchers at the University of Grenoble, in France, have discovered that erythropoietin administration prevents acute cardiotoxic effects induced by doxorubicin and trastuzumab exposures. The research article describing this work entitled Erythropoietin pretreatment protects against acute chemotherapy toxicity in isolated rat hearts will be featured in the January 2008 issue of Experimental Biology and Medicine. Although rare, cardiotoxicity is a serious complication of cancer treatment. Indeed, the use of chemotherapeutic agents such as anthracycline or trastuzumab in oncology is limited by their cardiac toxicity. Therefore, it is of interest to identify new protective agents preventing these adverse effects.

The increasing use of doxorubicin and trastuzumab in adjuvant breast cancer therapy and the growing population of long-term pediatric cancer survivors mean that, more than ever, cardiotoxicity will continue to remain an important issue for oncology. Cardiomyopathy induced by chronic chemotherapy may result, at least in part, from acute cardiotoxic effects accompanying each drug exposure. said Professor Mireille Mousseau, head of the Department of Oncology.

The research team, led by Christophe Ribuot, a professor of pharmacology, explored the beneficial cardioprotective effect afforded by recombinant human erythropoietin (rhEPO) against various stresses, through experimental and clinical investigations.

This study is an excellent illustration of a fruitful collaboration between researchers in experimental pharmacology, Christophe Ribuot and Marie Joyeux-Faure, and the oncologist M. Mousseau. Here, we observed for the first time that only a unique rhEPO administration prevents cardiac damage induced by an acute doxorubicin or trastuzumab exposure, using the isolated rat heart model. said the articles first author Amandine Ramond. RhEPO administration could, therefore, be used during chemotherapy administration to reduce acute cardiotoxic effects accompanying each drug exposure and, potentially, to prevent long-term development of cardiomyopathy. Further clinical investigations are now needed to explore the potential benefit of rhEPO in oncology.

Dr. Steven R. Goodman, Editor-in-Chief of Experimental Biology and Medicine, said Amandine Ramond and her colleagues have provided an insightful study demonstrating that rhEPO can reduce the cardiotoxic effects of chemotherapeutic agents, doxorubicin and trastzumab, in a rat heart model. If rhEPO has similar effects on humans then this study will be of substantial benefit to cancer patients worldwide.


Contact: Dr. Marie Faure
Society for Experimental Biology and Medicine

Related biology news :

1. Research shows skeleton to be endocrine organ
2. Newly created cancer stem cells could aid breast cancer research
3. Dominant cholesterol-metabolism ideas challenged by new research
4. Researchers identify proteins involved in new neurodegenerative syndrome
5. Texas researchers and educators head for Antarctica
6. MGH researchers describe new way to identify, evolve novel enzymes
7. University of Pennsylvania researchers develop formula to gauge risk of disease clusters
8. University of Oregon researcher finds that on waters surface, nitric acid is not so tough
9. U of MN researchers discover noninvasive diagnostic tool for brain diseases
10. U of Minnesota researchers discover noninvasive diagnostic tool for brain diseases
11. Story ideas from the Journal of Lipid Research
Post Your Comments:
(Date:11/9/2015)... 09, 2015 ... the "Global Law Enforcement Biometrics Market ... --> ) has announced the ... Biometrics Market 2015-2019" report to their ... ( ) has announced the addition ...
(Date:10/29/2015)...   MedNet Solutions , an innovative SaaS-based eClinical ... research, is pleased to announce that it has been ... one of only three finalists for a 2015 ... Growing" category. The Tekne Awards honor Minnesota ... innovation and leadership. iMedNet™ eClinical ...
(Date:10/29/2015)... Oct. 29, 2015  Connected health pioneer, Joseph ... explosion of technology-enabled health and wellness, and the business ... The Internet of Healthy Things . ... smartphones even existed, Dr. Kvedar, vice president, Connected Health, ... care delivery, moving care from the hospital or doctor,s ...
Breaking Biology News(10 mins):
(Date:11/24/2015)... --> --> ... by Transparency Market Research, the global non-invasive prenatal testing ... 17.5% during the period between 2014 and 2022. The ... Analysis, Size, Volume, Share, Growth, Trends and Forecast 2014 ... to reach a valuation of US$2.38 bn by 2022. ...
(Date:11/24/2015)... ... November 24, 2015 , ... In harsh industrial ... points for in-line sensors can represent a weak spot where leaking process media ... of retractable sensor housings , which are designed to tolerate extreme process conditions. ...
(Date:11/24/2015)... LOS ANGELES , Nov. 24, 2015 ... a biotechnology company focused on the discovery, development and ... Marban , Ph.D., Chief Executive Officer, is scheduled to ... December 1, 2015 at 10:50 a.m. EST, at The ... York City . . ...
(Date:11/24/2015)... ... , ... Whitehouse Laboratories is pleased to announce that it has completed construction ... dedicated to basic USP 61, USP 62 and USP 51 testing specific to raw ... and micro testing performed by one supplier. Management has formally announced that ...
Breaking Biology Technology: